Table 3.

Analysis of the average and average absolute value QTc interval changes at different study time points in in the cetuximab-IRDye800CW trial and the panitumumab-IRDye800CW trial.

	Cetuximab-IRDye800CW	Panitumumab-IRDye800CW	p-value
Post-Loading Dose
Average QTc Change (%)	n.d.	2.2 ± 4.5
Average Absolute QTc Change (%)		4.1 ± 2.8
Post-Infusion of Antibody-Dye Complex
Average QTc Change (%)	1.1 ± 4.5	1.3 ± 5.0	0.9
Average Absolute QTc Change (%)	3.3 ± 2.3	3.6 ± 3.5	0.8
30 Days Post-Infusion
Average QTc Change (%)	0.5 ± 5.7	2.9 ± 5.2	0.3
Average Absolute QTc Change (%)	4.2 ± 3.	3.4 ± 4.8	0.6

n.d.: not determined.